ATP1A2

Across TCGA pan-cancer cohorts, ATP1A2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP1A2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATP1A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP1A2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LSCC, GBM, and HNSC are the cancer types where ATP1A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.206	0.809	.004	21	view →
GBM	OS	Quartile	All	0.621	0.288	.004	7	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP1A2–LSCC (DFS)

Open the LSCC breakdown →